Carbetocin is a synthetic oxytocin analog used to induce labor or as a tocolytic. It is indicated to control postpartum hemorrhage due to uterine atony associated with uterine inertia, as well as in the prevention and treatment of uterine muscle syndrome during the third trimester of pregnancy. It is available in injection form in a 20ml vial.
Carbetocin is mainly used to induce labor and control postpartum hemorrhage associated with uterine atony due to uterine inertia. Additionally, it can also be used to prevent and treat uterine muscle syndrome during the third trimester of pregnancy.
The active component of the drug, Carbetocin , is a delta receptor agonist with a much higher potency than oxytocin. Its mechanism of action involves binding to isotocin receptors, which are expressed in both the myometrium and endometrium, to induce uterine contraction. Additionally, carbetocin has vasopressin-like properties, which can lead to vasoconstriction. This results in improved uterine perfusion, delaying postpartum hemorrhage.
Carbetocin starts to work within 5-10 minutes after administration and its effects can last anywhere from 2-4 hours. In some cases, it can take up to 30 minutes for the drug to start producing its effects.
Carbetocin is rapidly and completely absorbed after intravenous administration.
Carbetocin is mainly eliminated via renal excretion. After intravenous administration, there is typically a rapid decline in plasma levels over 4 to 6 hours, with a median elimination half life of 3.7 hours.
The recommended dose of Carbetocin is 2 mL, corresponding to 100 mcg given intravenously, which is repeated 1 to 4 hours depending on the intensity of uterine contractions. If the effect does not occur, a further single dose can be used up to 8 hours after the previous dose. The maximum dose is 500 mcg over a 24-hour period.
Carbetocin should be administered intravenously at a rate of 1 mL per minute. It should not be administered intramuscularly or subcutaneously.
Common side effects of Carbetocin include headache, dizziness, nausea, vomiting, abdominal discomfort, diarrhea, flushing, hypertension, and tachycardia. Rarely, more serious side effects such as pulmonary edema, arrhythmia, and cardiac arrest have been reported.
The pharmacologic effects of Carbetocin are dose-dependent. Overdoses of Carbetocin can result in an excessive uterine contraction, which can lead to uterine rupture. Additionally, it is important to note that the maximum recommended dose of Carbetocin is 500 mcg over a 24-hour period.
Carbetocin should not be used in individuals with hypothyroidism, adrenal insufficiency, hypertension, cardiac disorders, and hepatic impairment. Additionally, Carbetocin should not be used in individuals with previous cesarean delivery or induced labor. Finally, special caution should be taken when administering Carbetocin to geriatric patients or those with high-risk factors for adverse reactions.
Carbetocin is known to interact with antidiuretic hormones such as vasopressin and methothine, as well as with drugs used to treat hypertension and diabetes.
Carbetocin is contraindicated in individuals with congenital or acquired uterine abnormalities, as it can cause uterine rupture. Additionally, it is contraindicated in individuals with oligohydramnios, postpartum infection, and prior myocardial infarction.
Carbetocin is known to interact with drugs used in the treatment of hypertension, diabetes, and antidiuretic hormones. Therefore, it is recommended to closely monitor the patient's response and blood pressure when administering Carbetocin in combination with these drugs.
Carbetocin should be taken approximately 30 minutes before meal or 2 hours after meal. Additionally, antacid medications should not be taken within 2 hours of administering Carbetocin as they could interfere with absorption.
Carbetocin is not recommended for use in pregnant women, as it has the potential to cause uterine contractions that could lead to uterine rupture. If necessary, it should be used in pregnant women only after careful consideration of the potential risks.
Carbetocin should not be used in nursing mothers, as it is not known whether or not it is excreted in breast milk. If necessary, it should be used in nursing mothers only after careful consideration of the potential risks.
Carbetocin should not be used in excess of the recommended dose due to the possibility of excessive uterine contractions leading to uterine rupture. In case of acute overdose, supportive measures should be taken as necessary.
Carbetocin is contraindicated in individuals with congenital or acquired uterine abnormalities, as it can cause uterine rupture. Additionally, it is contraindicated in individuals with hypothyroidism, adrenal insufficiency, hypertension, cardiac disorders, hepatic impairment, prior myocardial infarction, oligohydramnios, and postpartum infection.
Carbetocin should be dissolved in 10 ml of sterile water prior to administration. The recommended dose is 2 mL (100 mcg), which should be administered intravenously at a rate of 1 mL per minute. It should not be administered intramuscularly or subcutaneously. The maximum dose is 500 mcg over a 24-hour period.
Carbetocin should be stored in a cool (5°C - 30°C) and dry place away from direct sunlight or moisture.
The volume of distribution of Carbetocin is not known.
After intravenous administration, the elimination half life of Carbetocin is 3.7 hours.
The clearance of Carbetocin is not known.
See in details version Carbetocin also Carbetocin in bangla
Prof. Dr. Md. Shah Alam
Mental Diseases, Drug Addiction, Sexual Health Specialist & Psychotherapist
Psychologist in Dhaka